Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Genasys (GNSS) Cash & Equivalents: 2010-2025

Historic Cash & Equivalents for Genasys (GNSS) over the last 16 years, with Sep 2025 value amounting to $8.0 million.

  • Genasys' Cash & Equivalents rose 61.15% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 61.15%. This contributed to the annual value of $8.0 million for FY2025, which is 61.15% up from last year.
  • Genasys' Cash & Equivalents amounted to $8.0 million in Q3 2025, which was up 49.26% from $5.3 million recorded in Q2 2025.
  • Genasys' Cash & Equivalents' 5-year high stood at $18.5 million during Q1 2021, with a 5-year trough of $3.0 million in Q2 2023.
  • Over the past 3 years, Genasys' median Cash & Equivalents value was $5.7 million (recorded in 2025), while the average stood at $6.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 74.66% in 2023, then spiked by 191.89% in 2024.
  • Quarterly analysis of 5 years shows Genasys' Cash & Equivalents stood at $10.1 million in 2021, then dropped by 25.38% to $7.6 million in 2022, then crashed by 36.80% to $4.8 million in 2023, then skyrocketed by 77.18% to $8.5 million in 2024, then skyrocketed by 61.15% to $8.0 million in 2025.
  • Its Cash & Equivalents stands at $8.0 million for Q3 2025, versus $5.3 million for Q2 2025 and $5.7 million for Q1 2025.